Progress in study of antiviral effect of chronic hepatitis B

CAO Yue; QIAN Qijun

doi:10.3969/j.issn.1006-0111.2015.06.022

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 33 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2015 > 33(6): 561-565

CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022

Citation:

CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022

Progress in study of antiviral effect of chronic hepatitis B

doi: 10.3969/j.issn.1006-0111.2015.06.022

CAO Yue¹,
QIAN Qijun^2
,

1.
First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China;Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China
2.
Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

Received Date: 2015-02-10
Rev Recd Date: 2015-07-13

Abstract

Chronic hepatitis B is a worldwide infectious diseases caused by hepatitis B virus (HBV). HBV infection is an important reason for liver cirrhosis and liver cancer in our country. Currently, the interferon and nucleoside analogs antiviral drugs (nucleotides) is widely used in clinical practice. These drugs inhibit the replication of the virus and disease development to a certain extent, but not fundamentally eliminate the virus. Various therapeutic vaccines have also made certain curative effect in anti HBV, but the effect is not perfect clinically. At present, many research Results demonstrate that biological immunotherapy can successfully eliminate HBV virus in the body, therefore it has brought a new hope for the treatment of hepatitis B.
- hepatitis B virus,
- nucleoside analogues,
- interferons,
- therapeutic vaccines,
- biological immunotherapy

References

[1]	Robinson WS, Lutwick LI, et al. The virus of hepatitis, type B(fist of two parts)[J]. N Engl J Med,1976,295:1168-1175.
[2]	Ito K, Qin Y, Guarnieri M, et al.Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein andrescue by a novel glycosylation site[J]. Virol,2010,84:12850-12861.
[3]	Shin D, Kim SI, Kim M, et al.Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene inmice[J]. Virus Res,2006,119:146-153.
[4]	Roingeard P,Lu SL,Sureau C,et al.Immunocytochemical and electron microscopic study of hepatitis B virus antigen and complete particle production in hepatitis B virus DNA transfected HepG2 cells[J].Hepatology,1990,11(2):277-285.
[5]	Kanto T,Inoue M,Miyatake H,et al.Reduced number impaired ability of myeloid and plasmacytoid dendritic cell polarize T helper cells in chronic hepatitis C virus infection[J].J Infect Dis,2004,190(11):1919-1926.
[6]	van der Molen RG,Sprengers D,Binda RS,et al .Function impairment of myeloid and plasmacytoid dendritic cells tients with chronic hepatitis B[J].Hepatology,2004,40(3):738-746.
[7]	Stoop JN,van der Molen RG,Baan CC,et al.Regulatory cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology,2005,41(4):771-778.
[8]	Xu D,Fu J,Jin L,et al.Circulating and liver resident CD4,CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B[J].J Immunol, 2006,177(1):739-747.
[9]	Sandalova E,Laccabue D,Boni C,et al.Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells[J].Gastroenterology,2012,143(1):78-87.
[10]	Zhang Z,Zhang S,Zou Z,et al.Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients[J].Hepatology,2011,53(1):73-85.
[11]	Fattovich G, Stroffolini T, Zagni I,et al.Hepatocellular carcinoma in cirrhosis: incidence and risk factors[J]. Gastroenterology,2004,127(5 suppl 1): S35-S50.
[12]	Janssen HL, van Zonneveld M, Senturk H,et al.Pegylated interferon-alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:arandomised trial[J].Lancet, 2005,365(9454):123-129.
[13]	Lau GK, Piratvisuth T, Luo KX,et al.Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2005,352(26):2682-2695.
[14]	Dienstag JL.Drug therapy: hepatitis B virus infection[J].N Engl J Med,2008,359:1486-500.
[15]	Gish RG, Lok AS, Chang TT,et al. Entecavir therapy for up to 96 weeks inpatients with HBeAg-positive chronic hepatitis B[J]. Gastroenterology,2007,133: 1437-1444.
[16]	Zoutendijk R, Reijnders JG, Zoulim F,et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut,2013,62: 760-765.
[17]	Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon-alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B.An Italian multicenter, randomized trial[J]. Hepatol,2001,35:406-411.
[18]	Petersen J, Ratziu V, Buti M,et al.Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study[J]. Hepatol,2012,56(3): 520-526.
[19]	Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and the rapeutic potential[J].Pathol Biol,2010, 58(4):288-295.
[20]	Sheppard CW, Samar EP,Finely L,et al.Hepatitis B virus infection: epidemiol and vaccination[J].Epidemiol Rev,2006,28:112-125.
[21]	Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan[J]. JAMA,1996, 276(11):906-908.
[22]	贺学新.非核苷类似药物在慢性乙肝治疗中的应用[J].现代医药卫生,2008,24(5):717- 718.
[23]	Betaneourt AA.Phase I clinical trial in healthy adults of a nasalvaccine candidate containing recombinant hepatitis B surface and core antigens[J].Int J Infect Dis,2007,11(5):394-401.
[24]	Hu ZB, Liu Y, Zhai XJ, et al.New loci associated with chronic hepatitis B virus infection in Han Chinese[J].Nat Genet,2013,45(12):1499-1503.
[25]	Rehermann B.IntrahepaticT cells in Hepatitis B:viral control versus liver cell injury[J].J Exp Med,2000,191:1263-1268.
[26]	Bertoletti A,Ferrari C.Kinetics of the immune response during HBV and HCV infection[J].Hepatology,2003,38(1):4-13.
[27]	Shiina S, Fujino H, Uta Y, et al.Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I: analysis of 1744 HBsAg carriers[J].Am J Gastroenterol, 1991,86(7):866-871.
[28]	Chen X, Tang Y, Zhang Y,et al.Peietal Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo[J].Lab Invest, 2014,94(5):478-490.
[29]	Pan XW, Ding HG, Zhou XY,et al.Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*33:03 in peripheral blood mononuclear cells from patients and transgenic mice[J].Biochem Biophys Res Commun,2014,449:135-140.
[30]	Ito H, Hoshi M, Ohtaki H,et al. Ability of IDO to attenuate liver injury in a-galactosylceramide-induced hepatitis model[J].J Immunol,2010,185(8):4554-4560.
[31]	Ito H, Seishima M. Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell[J]. Biomed Biotechnol,2010,10:641-757.
[32]	Kim D, Hung CF, Wu TC,et al. DNA vaccine with a-galactosylceramide at primephase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells[J]. Vaccine,2010, 28:7297-305.
[33]	Ito H, Ando K, Ishikawa T, et al. Role of Va14+ NKT cells in the development of hepatitis B virus-specific CTL: activation of Va14+ NKT cells promotes the breakage of CTL tolerance[J]. Int Immunol,2008,20:869-879.
[34]	Akbar SM, Chen S, Al-Mahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccinesin a murine model of chronic hepatitis B: HBcAg is a candidate for atherapeutic vaccine against hepatitis B virus[J]. Antiviral Res,2012,96:59-64.
[35]	Chen W, Shi M, Shi F, et al. HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes[J]. Hepatol Res,2009,39:355-365.
[36]	Chen X, Liu H, Tang Z, et al. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellular delivered CTL epitopes via cytoplasmic transduction peptide[J]. Acta Biochim Biophys Sin(ABBS,Shanghai), 2013,45(3):203-212.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2771) PDF downloads(336) Cited by()

Proportional views

Progress in study of antiviral effect of chronic hepatitis B

1. First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China;Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

2. Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

Received Date: 2015-02-10

Rev Recd Date: 2015-07-13

Key words:

Abstract: Chronic hepatitis B is a worldwide infectious diseases caused by hepatitis B virus (HBV). HBV infection is an important reason for liver cirrhosis and liver cancer in our country. Currently, the interferon and nucleoside analogs antiviral drugs (nucleotides) is widely used in clinical practice. These drugs inhibit the replication of the virus and disease development to a certain extent, but not fundamentally eliminate the virus. Various therapeutic vaccines have also made certain curative effect in anti HBV, but the effect is not perfect clinically. At present, many research Results demonstrate that biological immunotherapy can successfully eliminate HBV virus in the body, therefore it has brought a new hope for the treatment of hepatitis B.

HTML

Reference (36)

[1]	Robinson WS, Lutwick LI, et al. The virus of hepatitis, type B(fist of two parts)[J]. N Engl J Med,1976,295:1168-1175.
[2]	Ito K, Qin Y, Guarnieri M, et al.Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein andrescue by a novel glycosylation site[J]. Virol,2010,84:12850-12861.
[3]	Shin D, Kim SI, Kim M, et al.Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene inmice[J]. Virus Res,2006,119:146-153.
[4]	Roingeard P,Lu SL,Sureau C,et al.Immunocytochemical and electron microscopic study of hepatitis B virus antigen and complete particle production in hepatitis B virus DNA transfected HepG2 cells[J].Hepatology,1990,11(2):277-285.
[5]	Kanto T,Inoue M,Miyatake H,et al.Reduced number impaired ability of myeloid and plasmacytoid dendritic cell polarize T helper cells in chronic hepatitis C virus infection[J].J Infect Dis,2004,190(11):1919-1926.
[6]	van der Molen RG,Sprengers D,Binda RS,et al .Function impairment of myeloid and plasmacytoid dendritic cells tients with chronic hepatitis B[J].Hepatology,2004,40(3):738-746.
[7]	Stoop JN,van der Molen RG,Baan CC,et al.Regulatory cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology,2005,41(4):771-778.
[8]	Xu D,Fu J,Jin L,et al.Circulating and liver resident CD4,CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B[J].J Immunol, 2006,177(1):739-747.
[9]	Sandalova E,Laccabue D,Boni C,et al.Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells[J].Gastroenterology,2012,143(1):78-87.
[10]	Zhang Z,Zhang S,Zou Z,et al.Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients[J].Hepatology,2011,53(1):73-85.
[11]	Fattovich G, Stroffolini T, Zagni I,et al.Hepatocellular carcinoma in cirrhosis: incidence and risk factors[J]. Gastroenterology,2004,127(5 suppl 1): S35-S50.
[12]	Janssen HL, van Zonneveld M, Senturk H,et al.Pegylated interferon-alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:arandomised trial[J].Lancet, 2005,365(9454):123-129.
[13]	Lau GK, Piratvisuth T, Luo KX,et al.Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2005,352(26):2682-2695.
[14]	Dienstag JL.Drug therapy: hepatitis B virus infection[J].N Engl J Med,2008,359:1486-500.
[15]	Gish RG, Lok AS, Chang TT,et al. Entecavir therapy for up to 96 weeks inpatients with HBeAg-positive chronic hepatitis B[J]. Gastroenterology,2007,133: 1437-1444.
[16]	Zoutendijk R, Reijnders JG, Zoulim F,et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut,2013,62: 760-765.
[17]	Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon-alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B.An Italian multicenter, randomized trial[J]. Hepatol,2001,35:406-411.
[18]	Petersen J, Ratziu V, Buti M,et al.Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study[J]. Hepatol,2012,56(3): 520-526.
[19]	Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and the rapeutic potential[J].Pathol Biol,2010, 58(4):288-295.
[20]	Sheppard CW, Samar EP,Finely L,et al.Hepatitis B virus infection: epidemiol and vaccination[J].Epidemiol Rev,2006,28:112-125.
[21]	Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan[J]. JAMA,1996, 276(11):906-908.
[22]	贺学新.非核苷类似药物在慢性乙肝治疗中的应用[J].现代医药卫生,2008,24(5):717- 718.
[23]	Betaneourt AA.Phase I clinical trial in healthy adults of a nasalvaccine candidate containing recombinant hepatitis B surface and core antigens[J].Int J Infect Dis,2007,11(5):394-401.
[24]	Hu ZB, Liu Y, Zhai XJ, et al.New loci associated with chronic hepatitis B virus infection in Han Chinese[J].Nat Genet,2013,45(12):1499-1503.
[25]	Rehermann B.IntrahepaticT cells in Hepatitis B:viral control versus liver cell injury[J].J Exp Med,2000,191:1263-1268.
[26]	Bertoletti A,Ferrari C.Kinetics of the immune response during HBV and HCV infection[J].Hepatology,2003,38(1):4-13.
[27]	Shiina S, Fujino H, Uta Y, et al.Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I: analysis of 1744 HBsAg carriers[J].Am J Gastroenterol, 1991,86(7):866-871.
[28]	Chen X, Tang Y, Zhang Y,et al.Peietal Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo[J].Lab Invest, 2014,94(5):478-490.
[29]	Pan XW, Ding HG, Zhou XY,et al.Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*33:03 in peripheral blood mononuclear cells from patients and transgenic mice[J].Biochem Biophys Res Commun,2014,449:135-140.
[30]	Ito H, Hoshi M, Ohtaki H,et al. Ability of IDO to attenuate liver injury in a-galactosylceramide-induced hepatitis model[J].J Immunol,2010,185(8):4554-4560.
[31]	Ito H, Seishima M. Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell[J]. Biomed Biotechnol,2010,10:641-757.
[32]	Kim D, Hung CF, Wu TC,et al. DNA vaccine with a-galactosylceramide at primephase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells[J]. Vaccine,2010, 28:7297-305.
[33]	Ito H, Ando K, Ishikawa T, et al. Role of Va14+ NKT cells in the development of hepatitis B virus-specific CTL: activation of Va14+ NKT cells promotes the breakage of CTL tolerance[J]. Int Immunol,2008,20:869-879.
[34]	Akbar SM, Chen S, Al-Mahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccinesin a murine model of chronic hepatitis B: HBcAg is a candidate for atherapeutic vaccine against hepatitis B virus[J]. Antiviral Res,2012,96:59-64.
[35]	Chen W, Shi M, Shi F, et al. HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes[J]. Hepatol Res,2009,39:355-365.
[36]	Chen X, Liu H, Tang Z, et al. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellular delivered CTL epitopes via cytoplasmic transduction peptide[J]. Acta Biochim Biophys Sin(ABBS,Shanghai), 2013,45(3):203-212.

Message Board

Progress in study of antiviral effect of chronic hepatitis B

doi: 10.3969/j.issn.1006-0111.2015.06.022

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views